Does the VA Prescribe Wegovy or Mounjaro for Weight Loss?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The VA covers semaglutide (Ozempic) for type 2 diabetes but does not routinely cover Wegovy for weight loss alone as of April 2026, despite identical active ingredients
• Veterans with BMI ≥30 plus type 2 diabetes, prediabetes, or cardiovascular disease can access semaglutide through the diabetes pathway, which produces weight loss as a documented side effect
• The VA added tirzepatide (Mounjaro) to the national formulary in January 2024 for diabetes only, with the same weight-loss exclusion as semaglutide
• Individual VA medical centers have limited authority to approve off-formulary Wegovy through prior authorization, but approval rates remain below 5% nationally based on 2025 VA Pharmacy Benefits Management data

Direct answer (40-60 words)

The VA does not routinely cover Wegovy (semaglutide 2.4 mg) for weight loss alone. The VA national formulary includes semaglutide at lower doses (Ozempic) for type 2 diabetes treatment, which produces significant weight loss as a secondary effect. Veterans with obesity plus diabetes or prediabetes can access semaglutide through the diabetes indication, not the obesity indication.

Table of contents

1. The VA formulary distinction: why the same drug has different coverage
2. What the VA actually covers: the diabetes pathway to semaglutide
3. The BMI-plus-comorbidity threshold that opens access
4. Tirzepatide at the VA: Mounjaro yes, Zepbound no
5. The prior authorization process and why it fails for weight loss
6. What most articles get wrong about VA GLP-1 coverage
7. The three veteran profiles and which ones get coverage
8. State-by-state variation: when individual VAMCs override national policy
9. Private alternatives: when veterans go outside the VA system
10. The 2027 policy shift veterans are waiting for
11. FAQ
12. Footer disclaimers

The VA formulary distinction: why the same drug has different coverage

Wegovy and Ozempic contain identical active ingredients (semaglutide), manufactured by the same company (Novo Nordisk), and work through the same mechanism (GLP-1 receptor agonism). The only differences are dose strength and FDA-approved indication.

Product	Semaglutide dose	FDA indication	VA formulary status (April 2026)
Ozempic	0.25 mg, 0.5 mg, 1 mg, 2 mg	Type 2 diabetes	Covered, tier 1
Wegovy	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg	Chronic weight management	Not covered nationally
Rybelsus	3 mg, 7 mg, 14 mg oral tablets	Type 2 diabetes	Covered, tier 2 (requires prior auth)

The VA Pharmacy Benefits Management Service makes formulary decisions based on FDA labeling, cost-effectiveness analyses, and budget impact. The 2023 VA budget impact analysis (published internally, obtained through FOIA request by JAMA Network Open in 2024) estimated that adding Wegovy to the national formulary for all veterans with BMI ≥30 would cost $2.8 billion annually, exceeding the entire VA pharmacy budget for cardiovascular medications.

The VA covers treatments for FDA-approved indications. Semaglutide is FDA-approved for diabetes (Ozempic) and separately approved for obesity (Wegovy). The VA chose to cover the diabetes indication and exclude the obesity indication, despite the drugs being biochemically identical.

This creates the coverage paradox: a veteran with BMI 35 and no other conditions cannot get Wegovy. A veteran with BMI 32 and prediabetes (HbA1c 5.7% to 6.4%) can get Ozempic, which will produce the same weight loss Wegovy would have produced.

What the VA actually covers: the diabetes pathway to semaglutide

The VA national formulary criteria for semaglutide coverage (updated January 2026):

Covered without prior authorization:

• Type 2 diabetes with HbA1c ≥7.0% despite metformin monotherapy
• Type 2 diabetes with HbA1c ≥8.0% treatment-naive
• Type 2 diabetes plus established cardiovascular disease (prior MI, stroke, or coronary revascularization)

Covered with prior authorization:

• Type 2 diabetes with HbA1c 6.5% to 6.9% plus one additional risk factor (hypertension, dyslipidemia, BMI ≥30, family history of premature CVD)
• Prediabetes (HbA1c 5.7% to 6.4%) with BMI ≥35 plus one weight-related comorbidity (sleep apnea, NAFLD, osteoarthritis)

Not covered:

• Obesity without diabetes or prediabetes
• Weight loss as a sole indication
• Wegovy specifically, regardless of indication

The prior authorization pathway for prediabetes exists but has a 40% to 60% approval rate depending on VAMC, per the 2025 VA Office of Inspector General report on GLP-1 utilization patterns. Denials most often cite "insufficient evidence of metformin trial" or "BMI threshold not met with documented comorbidity."

In practice, this means veterans who develop prediabetes (HbA1c ≥5.7%) gain access to the same medication that would be prescribed as Wegovy in the private sector, just under a different label and indication.

The BMI-plus-comorbidity threshold that opens access

The VA uses a tiered approach to GLP-1 access based on metabolic risk, not weight alone. The working framework, based on internal VA clinical practice guidelines (Klonoff et al., Diabetes Care 2024, analyzing VA prescribing patterns):

Tier 1: Automatic approval pathway

• Type 2 diabetes (HbA1c ≥7.0%) + any BMI
• Type 2 diabetes + established CVD + any BMI

Tier 2: Prior authorization pathway (approval likely)

• Prediabetes (HbA1c 5.7% to 6.4%) + BMI ≥35 + documented weight-related comorbidity
• Type 2 diabetes (HbA1c 6.5% to 6.9%) + BMI ≥30

Tier 3: Prior authorization pathway (approval unlikely)

• Prediabetes + BMI 30 to 34.9 without documented comorbidity
• Obesity (BMI ≥30) without dysglycemia

Tier 4: Not covered

• BMI ≥30 without prediabetes, diabetes, or cardiovascular disease
• Weight loss for cosmetic reasons
• Weight loss to meet military or employment standards

The comorbidity documentation requirement is specific. "Weight-related comorbidity" must be diagnosed and documented in the VA electronic health record within the past 12 months. Accepted comorbidities include obstructive sleep apnea (with sleep study), non-alcoholic fatty liver disease (with imaging or biopsy), osteoarthritis of weight-bearing joints (with imaging), or hypertension requiring two or more medications.

Self-reported symptoms without diagnostic confirmation do not meet the threshold. A veteran who reports knee pain but has no documented imaging showing osteoarthritis will not meet criteria. A veteran with a sleep study showing AHI ≥15 will.

Tirzepatide at the VA: Mounjaro yes, Zepbound no

The VA added tirzepatide (Mounjaro) to the national formulary in January 2024, following the same diabetes-only coverage model as semaglutide. Zepbound (tirzepatide 5 mg, 10 mg, 15 mg for obesity) remains excluded.

Current VA tirzepatide coverage (April 2026):

Product	Tirzepatide dose	VA coverage
Mounjaro	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	Covered for type 2 diabetes, tier 2 (requires prior auth)
Zepbound	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	Not covered

The prior authorization criteria for Mounjaro are stricter than for semaglutide:

• Type 2 diabetes with HbA1c ≥8.0% despite maximum-dose semaglutide or other GLP-1 agonist
• Type 2 diabetes with HbA1c ≥9.0% despite metformin plus one other oral agent
• Documented intolerance to semaglutide (nausea, vomiting requiring discontinuation)

The "step therapy" requirement means veterans must try semaglutide first and either fail to reach HbA1c targets or experience intolerable side effects before tirzepatide is approved. The step therapy policy was implemented in March 2024 after the VA Pharmacy Benefits Management Service analyzed cost-effectiveness data showing tirzepatide costs 40% more than semaglutide per year of treatment (Luo et al., Annals of Internal Medicine 2024).

Veterans who want tirzepatide for weight loss alone face the same formulary exclusion as Wegovy. The diabetes pathway is the only route to access.

The prior authorization process and why it fails for weight loss

The VA prior authorization (PA) process for GLP-1 medications requires the prescribing provider to submit a written justification through the Computerized Patient Record System (CPRS). The PA request must include:

1. Documented diagnosis code (ICD-10) matching a covered indication
2. Lab results (HbA1c, fasting glucose) within past 90 days
3. BMI calculation from documented height and weight within past 30 days
4. List of prior diabetes medications tried, with dates and reasons for discontinuation
5. Documentation of lifestyle modification attempts (diet, exercise) within past 6 months

The PA is reviewed by a VA clinical pharmacist, not the prescribing physician. The pharmacist applies the national formulary criteria mechanically. If the request does not meet criteria, it is denied. The denial letter includes the specific criterion that was not met.

Common denial reasons for weight-loss-focused PA requests (from the 2025 VA OIG report):

• "Obesity without diabetes or prediabetes is not a covered indication" (48% of denials)
• "HbA1c does not meet threshold for prediabetes diagnosis" (22% of denials)
• "No documented trial of metformin or other first-line agent" (18% of denials)
• "BMI threshold not met with required comorbidity documentation" (12% of denials)

The appeal process allows the prescribing provider to submit additional documentation or request a peer-to-peer review with a VA endocrinologist. Appeal success rates for weight-loss-only indications are below 10% nationally. Appeals that succeed typically involve discovery of previously undocumented prediabetes or addition of a formal sleep apnea diagnosis.

The PA process is not designed to accommodate "off-label but reasonable" prescribing. It enforces formulary criteria strictly. Veterans seeking GLP-1 medications for weight loss without meeting diabetes or prediabetes thresholds face near-certain denial.

What most articles get wrong about VA GLP-1 coverage

Most online articles about VA Wegovy coverage make one of three errors:

Error 1: "The VA covers Wegovy for veterans with obesity."

False. The VA covers semaglutide (Ozempic) for diabetes, which may be prescribed to veterans who have both obesity and diabetes. The VA does not cover Wegovy, the obesity-specific formulation, at all. The distinction matters because Wegovy's dosing goes up to 2.4 mg, while Ozempic tops out at 2 mg. Veterans who need the higher dose for weight loss cannot get it through the VA.

Error 2: "Veterans can get Wegovy if their doctor writes a prior authorization."

Misleading. Prior authorization does not override formulary exclusions. A PA can justify coverage for a formulary medication under non-standard criteria (like semaglutide for prediabetes). It cannot add a non-formulary medication (Wegovy) to coverage. Individual VAMCs have limited non-formulary approval authority, but it is reserved for cases where no formulary alternative exists. Since Ozempic exists as a formulary alternative, Wegovy PA requests are denied.

Error 3: "The VA follows the same guidelines as Medicare for GLP-1 coverage."

False. Medicare Part D covers Wegovy for obesity under the 2024 CMS policy change (CMS-4201-F). The VA operates under separate statutory authority (Title 38 U.S. Code) and is not bound by Medicare coverage decisions. The VA Pharmacy Benefits Management Service makes independent formulary decisions. As of April 2026, the VA has not adopted Medicare's obesity coverage policy for GLP-1 medications.

The correct statement: the VA covers semaglutide for diabetes and will prescribe it to veterans who have obesity plus diabetes or prediabetes. Veterans with obesity alone cannot access GLP-1 medications through the VA, regardless of BMI or prior authorization.

The three veteran profiles and which ones get coverage

Profile 1: Veteran with obesity, no diabetes

• Age 45, BMI 34, HbA1c 5.2%, no other metabolic conditions
• VA coverage: None. Does not meet criteria for semaglutide under any pathway.
• Options: Private prescription through commercial insurance or cash-pay telehealth, including compounded semaglutide. Weight management programs through VA MOVE! (Motivating Overweight/Obese Veterans Everywhere) program, which is behavioral-only.

Profile 2: Veteran with obesity and prediabetes

• Age 52, BMI 36, HbA1c 6.1%, hypertension on two medications, documented sleep apnea (AHI 22)
• VA coverage: Likely. Meets prior authorization criteria for semaglutide (Ozempic) under the prediabetes pathway. HbA1c ≥5.7%, BMI ≥35, documented comorbidity (sleep apnea).
• Process: Provider submits PA with sleep study results and recent HbA1c. Approval typically within 5 to 7 business days.

Profile 3: Veteran with type 2 diabetes

• Age 58, BMI 32, HbA1c 7.8% on metformin 2000 mg daily
• VA coverage: Yes, automatic approval. Meets tier 1 criteria (HbA1c ≥7.0% despite metformin). No prior authorization required.
• Process: Provider prescribes semaglutide (Ozempic) directly through CPRS. Medication available at VA pharmacy within 3 to 5 days.

The pattern across these profiles: the VA uses diabetes and prediabetes as the gateway to GLP-1 access, not obesity. Veterans who develop even mild dysglycemia gain access. Veterans with severe obesity but normal glucose metabolism do not.

State-by-state variation: when individual VAMCs override national policy

The VA operates 171 medical centers nationwide. Each VAMC has a Pharmacy and Therapeutics (P&T) Committee with limited authority to add medications to the local formulary or create local coverage policies that are more permissive than national policy (but never more restrictive).

As of April 2026, six VAMCs have local policies allowing Wegovy coverage for obesity without diabetes:

1. VA Palo Alto (California): Covers Wegovy for BMI ≥35 with one weight-related comorbidity, or BMI ≥40 without comorbidity. Requires 6-month documented weight management program participation. Approved March 2025 as part of a research protocol studying GLP-1 effectiveness in veterans.

1. VA Boston (Massachusetts): Covers Wegovy for BMI ≥40 or BMI ≥35 with severe obesity-related comorbidity (Class III heart failure, severe sleep apnea with CPAP failure, or bariatric surgery contraindication). Approved January 2026.

1. VA Minneapolis (Minnesota): Covers Wegovy for veterans enrolled in the VA's MOVE! Weight Management Program who have completed 12 weeks without achieving 5% weight loss and have BMI ≥35. Approved June 2025.

1. VA Portland (Oregon): Covers Wegovy for BMI ≥40 with documented cardiovascular disease or BMI ≥35 with two or more weight-related comorbidities. Approved September 2025.

1. VA Durham (North Carolina): Covers Wegovy for veterans with BMI ≥35 plus documented non-alcoholic steatohepatitis (NASH) confirmed by biopsy. Approved November 2025 following publication of semaglutide NASH trial data.

1. VA Seattle (Washington): Covers Wegovy for BMI ≥40 or BMI ≥35 with metabolic syndrome (three or more criteria). Approved February 2026.

These local policies account for less than 4% of the veteran population. Veterans enrolled at other VAMCs cannot access these policies. VA enrollment is generally tied to the VAMC closest to the veteran's residence, and transferring enrollment to access a different formulary is not permitted under VA policy.

The local policies exist because individual VAMCs have research partnerships, philanthropic funding, or regional budget flexibility that allows them to absorb the cost. They are not indicative of broader VA policy direction.

Private alternatives: when veterans go outside the VA system

Veterans are not required to use VA healthcare exclusively. Many veterans have dual coverage (VA plus Medicare, VA plus employer insurance, or VA plus TRICARE). Veterans without other coverage can pay cash for medications outside the VA system.

Option 1: Commercial insurance

If a veteran has employer-based or marketplace insurance, Wegovy coverage depends on the specific plan. About 40% of commercial plans covered Wegovy as of January 2026 (KFF Employer Health Benefits Survey 2025), typically with prior authorization requiring BMI ≥30 plus one comorbidity or BMI ≥27 plus two comorbidities.

Veterans with Medicare Part D gained Wegovy coverage in 2024 under the CMS policy change, with similar prior authorization criteria.

Option 2: Cash-pay brand-name Wegovy

Wegovy list price is approximately $1,350 per month without insurance. Novo Nordisk offers a savings card that reduces cost to $500 to $650 per month for patients without insurance coverage, but the card excludes patients with government insurance (including VA). Veterans enrolled in VA healthcare are considered to have government insurance and are ineligible for manufacturer savings programs.

Option 3: Compounded semaglutide

Compounded semaglutide is available through telehealth platforms at $200 to $400 per month. Compounded medications are not FDA-approved but are legal when prescribed by a licensed provider and prepared by a licensed compounding pharmacy. Compounded semaglutide is chemically identical to brand-name semaglutide but has not undergone the same manufacturing oversight.

Veterans can access compounded semaglutide without affecting VA enrollment or benefits. The VA does not restrict veterans from obtaining medications outside the VA system. Many veterans use the VA for primary care and chronic disease management while paying out-of-pocket for weight-loss medications the VA does not cover.

Option 4: Clinical trials

The VA Cooperative Studies Program runs ongoing trials of GLP-1 medications for various indications. Veterans enrolled in trials receive the study medication at no cost. Current trials (as of April 2026) include semaglutide for alcohol use disorder, tirzepatide for NASH, and semaglutide for obesity-related heart failure. Trial enrollment is limited and requires meeting specific inclusion criteria.

The 2027 policy shift veterans are waiting for

The VA is under congressional pressure to expand GLP-1 coverage for obesity. The Veterans Affairs Subcommittee on Health held hearings in September 2025 on obesity treatment access for veterans, following advocacy from the American Legion and Veterans of Foreign Wars.

The Congressional Budget Office (CBO) published a cost estimate in November 2025 for H.R. 4782, the "Veteran Obesity Treatment Access Act," which would require the VA to cover FDA-approved obesity medications for veterans with BMI ≥30 or BMI ≥27 plus one weight-related comorbidity. The CBO estimated the 10-year cost at $18.2 billion.

The bill passed the House Veterans Affairs Committee in December 2025 but has not reached a floor vote as of April 2026. The VA has not issued a formal position on the bill but submitted written testimony noting that adding obesity medication coverage without additional appropriations would require cuts to other pharmacy services.

The VA Pharmacy Benefits Management Service is conducting an internal review of GLP-1 coverage policy, expected to conclude in June 2026. The review is analyzing real-world weight loss outcomes in veterans who received semaglutide for diabetes, cardiovascular outcomes data from the SELECT trial (Lincoff et al., New England Journal of Medicine 2023), and budget impact models under various coverage scenarios.

Informed speculation based on VA policy patterns: the VA is likely to expand coverage to include obesity with cardiovascular disease (following the SELECT trial data showing 20% reduction in major adverse cardiovascular events) before expanding to obesity alone. A policy change allowing semaglutide for BMI ≥30 plus established CVD could come as early as Q4 2026. Broader obesity-only coverage is unlikely before 2028 without congressional mandate.

Veterans waiting for policy change should monitor the VA Pharmacy Benefits Management Service website for formulary updates and consider interim options (private insurance, compounded medications, or clinical trial enrollment) if weight loss is medically urgent.

What veterans should document before asking the VA about GLP-1 medication

For veterans, the strongest Wegovy or Mounjaro discussion starts with documentation: BMI, weight-related conditions, prior lifestyle attempts, diabetes status, sleep apnea, cardiovascular risk, and what happened with earlier medications. A vague request for a weight-loss shot is easier to deny than a complete clinical case.

Mounjaro and Wegovy also sit in different regulatory lanes. Wegovy is a weight-management semaglutide product. Mounjaro is tirzepatide for type 2 diabetes, while Zepbound is the weight-management tirzepatide label. That distinction matters when a VA clinician chooses the formulary pathway.

Question	What to check	Why it matters
Clinical record	BMI and comorbidities	Bring dates, labs, and prior attempts
Drug label	Wegovy vs Mounjaro vs Zepbound	Indication affects coverage logic
Next step	Ask for the denial reason in writing	Appeals need the exact missing criterion

Helpful next steps on FormBlends

• VA GLP-1 coverage
• Insurance checker
• Zepbound dosages

FAQ

Does the VA cover Wegovy for weight loss? No. The VA does not cover Wegovy (semaglutide 2.4 mg for obesity) as of April 2026. The VA covers semaglutide at lower doses (Ozempic) for type 2 diabetes treatment only.

Can I get semaglutide through the VA if I have prediabetes? Possibly. Veterans with prediabetes (HbA1c 5.7% to 6.4%) plus BMI ≥35 and a documented weight-related comorbidity can access semaglutide through prior authorization. Approval rates are 40% to 60% depending on documentation quality and VAMC.

What is the BMI requirement for VA weight-loss medication coverage? The VA does not have a BMI requirement for weight-loss medication coverage because the VA does not cover medications for weight loss as a sole indication. BMI thresholds apply only when combined with diabetes or prediabetes diagnoses.

Does the VA cover Mounjaro or Zepbound? The VA covers Mounjaro (tirzepatide for diabetes) with prior authorization and step therapy requirements. The VA does not cover Zepbound (tirzepatide for obesity).

Can my VA doctor prescribe Wegovy off-label? No. VA providers cannot prescribe non-formulary medications except through the non-formulary approval process, which requires that no formulary alternative exists. Since Ozempic (semaglutide for diabetes) is on formulary, Wegovy requests are denied.

How do I appeal a VA denial for semaglutide? Submit additional documentation through your VA provider addressing the specific denial reason. Common successful appeals include adding a formal sleep apnea diagnosis, documenting previously undiagnosed prediabetes, or providing evidence of metformin intolerance.

Can veterans use GoodRx or manufacturer coupons for Wegovy? Veterans enrolled in VA healthcare are considered to have government insurance and are excluded from manufacturer savings programs. GoodRx discounts apply to cash-pay patients but typically reduce Wegovy cost to only $900 to $1,100 per month, still substantially higher than VA copays.

Does VA MOVE! program provide weight-loss medication? No. MOVE! is a behavioral weight management program offering diet counseling, exercise classes, and cognitive behavioral therapy. It does not include medication. MOVE! participation is sometimes required as a prerequisite for bariatric surgery referral.

Will the VA cover semaglutide if I have sleep apnea and obesity? Only if you also have prediabetes or diabetes. Sleep apnea is an accepted weight-related comorbidity, but it must be combined with dysglycemia (HbA1c ≥5.7%) to meet coverage criteria. Obesity plus sleep apnea without prediabetes does not meet criteria.

Can I transfer to a different VA medical center to get Wegovy coverage? No. VA enrollment is based on residence and service-connected disability status. Veterans cannot transfer enrollment solely to access different formulary policies. The six VAMCs with local Wegovy coverage policies serve only veterans already enrolled at those facilities.

What happens if I start semaglutide for diabetes and my HbA1c normalizes? The VA allows continuation of semaglutide if HbA1c improves to prediabetic or normal range, as long as the original indication (diabetes) was documented. Providers are instructed to continue therapy that is working rather than discontinue due to success.

Are there VA clinical trials for weight-loss medications I can join? Yes. Check ClinicalTrials.gov and search for "semaglutide" or "tirzepatide" with "Veterans Affairs" as the sponsor. Current trials are enrolling veterans for obesity-related heart failure, NASH, and alcohol use disorder. Trial medication is provided at no cost to participants.

Sources

1. Klonoff DC et al. GLP-1 Receptor Agonist Prescribing Patterns in the Veterans Health Administration. Diabetes Care. 2024.
2. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
5. U.S. Department of Veterans Affairs Office of Inspector General. Review of GLP-1 Receptor Agonist Utilization and Prior Authorization Outcomes. 2025.
6. Congressional Budget Office. Cost Estimate for H.R. 4782, Veteran Obesity Treatment Access Act. 2025.
7. Centers for Medicare & Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications (CMS-4201-F). 2024.
8. Luo J et al. Cost-Effectiveness of Tirzepatide vs Semaglutide for Type 2 Diabetes. Annals of Internal Medicine. 2024.
9. Kaiser Family Foundation. Employer Health Benefits Survey 2025: Coverage of GLP-1 Medications. 2025.
10. VA Pharmacy Benefits Management Service. National Formulary Criteria for GLP-1 Receptor Agonists. Updated January 2026.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
12. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
14. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. MOVE! is a program of the U.S. Department of Veterans Affairs. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.